Karuna's Schizophrenia Drug Advances Towards 2024 Launch Despite Safety Concerns.
Karuna Therapeutics' investigational schizophrenia treatment, KarXT, has shown a statistically significant and clinically meaningful reduction in symptoms compared to placebo in another Phase III clinical trial. The biotech hopes to submit a mid-2023 approval request for the drug, which could open the doors for a new class of medication for the millions of people living with the disorder. Meanwhile, BioNTech has signed an exclusive deal with OncoC4 to co-develop and co-commercialize OncoC4’s monoclonal antibody candidate for a variety of cancer indications, paying $200 million upfront for ONC-392, OncoC4’s anti-CTLA-4 candidate.